Gilead Sciences (GILD) Convertible Debt (2009 - 2010)
Gilead Sciences (GILD) reported Convertible Debt of $2.8 billion for Q4 2010, up 145.67% on a YoY basis from $1.2 billion in Q4 2009, and up 0.7% quarter-over-quarter from $2.8 billion in Q3 2010.
Gilead Sciences (GILD) Convertible Debt (2009 - 2010) Analysis & Trends
Gilead Sciences has reported Convertible Debt for 2 years, with the latest figure at $2.8 billion in Q4 2010.
- For the quarter ending Q4 2010, Convertible Debt rose 145.67% year-over-year to $2.8 billion; the trailing twelve-month figure through Dec 2010 stood at $2.8 billion (up 145.67% YoY), and the FY2010 full-year result was $2.8 billion, up 145.67% from the prior year.
- Convertible Debt for Q4 2010 stood at $2.8 billion, up from $2.8 billion in the prior quarter.
- The five-year high for Convertible Debt was $2.8 billion in Q4 2010, with the low at $1.1 billion in Q2 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2010 | 2.84 Bn |
| Sep 30, 2010 | 2.82 Bn |
| Mar 31, 2010 | 1.17 Bn |
| Dec 31, 2009 | 1.16 Bn |
| Sep 30, 2009 | 1.14 Bn |
| Jun 30, 2009 | 1.13 Bn |